**Supplemental Appendix 2.** Characteristics of PE patients admitted during the TA+PERT time period (2016-2017)

|  |  |  |  |
| --- | --- | --- | --- |
| **Patient Characteristics** | **PERT** | **Non-PERT** | **p-value** |
| Total admissions | 87 | 324 |  |
| Male, n (%) | 56 (64.4) | 159 (49.1) | 0.011 |
| Age, mean (SD) | 64.1 (13.2) | 61.9 (16.3) | 0.201 |
| Weight(kg), mean (SD) | 103.2 (31.0) | 92.77 (30.6) | 0.006 |
| Troponin elevation (% elevated/measured) | 56 (90.3) | 68 (72.3) | 0.012 |
| BNP elevation (% elevated/measured) | 22 (64.7) | 17 (38.6) | 0.040 |
| SPESI > 0, n (%) | 64 (76.2) | 228 (71.3) | 0.368 |
| Lowest systolic blood pressure, mean (SD) | 98.5 (15.0) | 112.7 (17.30 | < 0.001 |
| Highest heart rate, mean (SD) | 95.8 (11.5) | 88.1 (11.2) | < 0.001 |
| ICU admission, n (%)  | 78 (89.7) | 70 (21.6) | < 0.001 |
| Past medical history, n (%) |  |  |  |
| Cancer | 19 (22.6) | 89 (27.8) | 0.339 |
| Congestive heart failure | 10 (11.9) | 46 (14.4) | 0.560 |
| COPD | 11 (13.1) | 110 (34.4) | < 0.001 |
| Chronic kidney disease | 7 (8.3) | 44 (13.8) | 0.183 |
| Diabetes mellitus | 18 (21.4) | 49 (15.3) | 0.180 |
| Hypertension | 51 (60.7) | 181 (56.6) | 0.493 |
| Sleep apnea | 13 (15.5) | 52 (16.3) | 0.864 |
| CAD | 25 (29.8) | 89 (27.8) | 0.724 |
| Tobacco use | 9 (10.7) | 33 (10.4) | 0.929 |
| **Patients treated with Reperfusion Therapy, n (%):** | 47 (54.0) | 19 (5.9) | < 0.001 |
| Massive PE, n (%)a | 7 (14.9) | 12 (63.2) | <0.001 |
| Massive, cardiac arrest, n (%)a | 4 (8.5) | 7 (36.8) | 0.010 |
| Submassive, n (%)a | 40 (85.1) | 7 (36.8) | <0.001 |
| SL, n (%)a | 38 (80.9) | 16 (84.2) | 1 |
| Reduced dose SL, n (%)a | 30 (63.8) | 6 (31.6) | 0.028 |
| CDI, n (%)a | 9 (19.1) | 3 (15.8) | 1 |

aPercentages calculated with the number of patients treated with Reperfusion Therapy as the denominator

BNP = brain natriuretic peptide; ICU = intensive care unit; PE = pulmonary embolism; SPESI = Simplified Pulmonary Embolism Severity Index.